Filing Flows › PAVmed (PAVM) › R&D spending
PAVmed (PAVM) R&D spending by quarter
PAVmed's R&D spending was $2.1M in Q2 2026 (second quarter 2026), +49% from Q1 2026. Over the last 6 quarters it ranged from $787K (Q1 2025) to $2.1M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.1M | +49% | +162% |
| Q1 2026 | $1.4M | -24% | +76% |
| Q4 2025 | $1.8M | +68% | — |
| Q3 2025 | $1.1M | +38% | — |
| Q2 2025 | $790K | +0.4% | — |
| Q1 2025 | $787K | — | — |
Q2 2026 at a glance
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is PAVmed's R&D spending?
PAVmed's R&D spending was $2.1M in Q2 2026 (second quarter 2026), +49% from Q1 2026.
How has PAVmed's R&D spending changed?
Over the last 6 quarters it ranged from $787K (Q1 2025) to $2.1M (Q2 2026).